If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Infectious factors === Nursing mothers diagnosed with yeast, bacterial, viral infections or dermatitis are susceptible to nipple pain. A type of yeast infection called candidiasis caused by a type of fungus called Candida will lead to itching, erythema of the nipple and areola, burning and stabbing nipple pain. It happens when the infant's mouth is infected by a Candida species called Candida albicans, the child may transmit the yeast to the mother's nipple during breastfeeding. Bacterial infection by Staphylococcus aureus (S.aureus) will give rise to mastitis which refers to an inflammation of the mammary gland. About half of the breastfeeding mothers reporting nipple ache were infected with S.aureus. They usually experienced a sudden onset and systemic symptoms including nipple pain, fever, flu-like symptoms, myalgia and fatigue. The risk of infections increases with an inhibition of mammary gland drainage. Viral infection with Herpes simplex virus (HSV) causes nipple ulceration, soreness and pain. Infants feeding on an HSV infected nipple can develop a life-threatening complication affecting the brain called encephalitis. Breastfeeding women with dermatitis problems, including psoriasis and eczema at the nipple, suffer from erythema, scaling lesion and pain. Nursing mothers with psoriasis may develop Koebner phenomenon upon further nipple abrasion by infants in prolonged breastfeeding. Eczema at the nipple can be caused by direct chemical contact or allergic condition. It affects the areola and sometimes extends to the breast.
== Television == Airwolf Danger Man, (Known as Secret Agent in the United States) I Led Three Lives – The first foray into mass culture dealing with the Cold War. I Spy (1965–68 US television series) Get Smart MacGyver The Man from U.N.C.L.E. Mission: Impossible Quatermass II Several episodes of Star Trek featured a futuristic version of the Cold War, in terms of the United Federation of Planets vs. The Klingon Empire and the Romulan Star Empire, analogs for the United States, the Soviet Union, and the People's Republic of China, respectively. "A Taste of Armageddon" also showed the concept of MAD in a war between opposing sides. Scarecrow and Mrs. King Ivan the Terrible 1976 sitcom The Rocky and Bullwinkle Show 1960s cartoon for children and adults where the villains are Boris and Natasha, who were both parodies of the Soviet spies. The Sandbaggers The Twilight Zone, a number of episodes of which depicted fallout shelters, such as the 1961 episode, The Shelter, produced as a social commentary on the Civil Defense push during the Berlin Crisis of 1961, and the 1987 Ronald Reagan era "Shelter Skelter". Twilight Zone episodes commenting on other aspects of the Cold War, and World Peace include the 1986 A Small Talent for War. The Transformers (TV series), including the fact that the two first seasons take place during the latter years of the Cold War, an episode, Prime Target directly refers to an event of the episode as The highest point of tension between United States and Soviet Union, since the Cuban Missile Crisis.
== History == The practice of salting fish dates back to ancient times. In classical antiquity, the town of Magdala on the Sea of Galilee, located in present-day Israel, was also known by its Greek name, Taricheae, meaning "place of fish salting." The Greek geographer Strabo even praised the quality of its fish (Geographica 16.2.45).
== External links == Distillation, An Introduction by Ming Tham, Newcastle University, UK Distillation Theory by Ivar J. Halvorsen and Sigurd Skogestad, Norwegian University of Science and Technology, Norway
Sources: en.wikipedia.org
=== Physical Activity/Exercise === Along with diet, physical activity is also important for the management of diabetes. Not only does exercising regularly help manage blood sugar levels and weight, it helps reduce the risk of heart attack and stroke, reduces cholesterol and blood pressure levels, reduces risk of diabetes related complications, increases the effect of insulin, provides a boost in energy levels, helps reduce stress, and contributes to positive self-esteem. By exercising, the body becomes more sensitive to insulin, allowing for better absorption of glucose by the muscle cells, for up to 24 hours after exercise. In addition, studies have shown that physical activity, even below recommended amounts, has the ability to reduce risk of diabetic-related complications. In people with type 2 diabetes, the combination of aerobic ("cardio") exercise and strength training is effective. Aerobic exercise has been shown to largely improve HbA1c, and contributes to weight loss and the enhanced regulation of cholesterol and lipoproteins. This may be any form of continuous exercise that elevates breathing and heart rate, such as walking, swimming, or dancing. During the last 20 years, resistance training has gained recognition as an effective form of exercise for people with type 2 diabetes. A light walk after a meal (postprandial walking) is also recognized as effective in reducing postprandial glucose spikes in people with or at risk for type 2 diabetes. In youths with type 1 diabetes, there is an association between exercise and lower HBA1c.
Travis Colyer's profile on the official website of the Fremantle Football Club Travis Colyer's playing statistics from AFL Tables Travis Colyer at AustralianFootball.com Travis Colyer's WAFL playing statistics at WAFLFootyFacts.net
==== Other treatments ==== Isotretinoin, a sebosuppressive agent, may be used to reduce sebaceous gland activity as a last resort in refractory disease. Isotretinoin has potentially serious side effects, and few patients with seborrhoeic dermatitis are appropriate candidates for therapy. Topical 0.75% and 1% Metronidazole Topical 4% nicotinamide Topical sulfacetamide Tea tree oil Cannabidiol shampoo Propanediol caprate Frequent washing to avoid the build-up of scale, especially on the scalp, while avoiding overly drying the skin Avoiding damaging skin with harsh grooming or chemical irritants Bicalutamide, an antiandrogen, has been observed in one patient to have potentially been the cause of seborrheic dermatitis relief. However, even if it were demonstrated that bicalutamide or any other antiandrogen is a treatment, it is not recommended due to side effects and price.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.